Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2769175 | 0.98 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1HRH3CYP1A2LMNA | |
| SCHEMBL18163286 | 0.90 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1HRH3CYP1A2LMNA | |
| SCHEMBL6643882 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1HRH3CYP1A2LMNA | |
| SCHEMBL22578221 | 0.86 | CYP1A2 (0.54) | SMN1; SMN2ALDH1A1HRH3CYP1A2LMNA | |
| SCHEMBL11769016 | 0.86 | CYP1A2 (0.54) | SMN1; SMN2ALDH1A1HRH3CYP1A2LMNA | |
| SCHEMBL11532136 | 0.84 | TDP1 (0.55) | SMN1; SMN2ALDH1A1HRH3CYP1A2LMNA | |
| SCHEMBL4341122 | 0.83 | LMNA (0.57) | SMN1; SMN2ALDH1A1CYP1A2LMNATDP1 | |
| SCHEMBL14640301 | 0.83 | HRH1 (0.52) | SMN1; SMN2ALDH1A1HRH3CYP1A2LMNA | |
| SCHEMBL9411265 | 0.83 | CYP1A2 (0.51) | SMN1; SMN2ALDH1A1HRH3CYP1A2LMNA | |
| SCHEMBL78000 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1CYP1A2LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5939268-A | DIELS-ALDER REACTION PRODUCT OF A DIENE AND A DIENOPHILE; CHEMICAL INTERMEDIATES FOR DRUGS, SOLID PHASE SYNTHESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| EP-0773953-A1 | COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME | THE SCRIPPS INSTITUTE (US) | 1997-05-21 | — | — | EP | claimed |
| WO-1996003424-A1 | COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-02-08 | — | — | WO | claimed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-107709334-B | Novel amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-04-13 | — | — | CN | disclosed |
| US-9957217-B2 | Conversion of alcohols to carboxylic acids using heterogeneous palladium-based catalysts | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170137362-A1 | CONVERSION OF ALCOHOLS TO CARBOXYLIC ACIDS USING HETEROGENEOUS PALLADIUM-BASED CATALYSTS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2017-05-18 | — | — | US | disclosed |
| US-9593064-B2 | Conversion of alcohols to alkyl esters and carboxylic acids using heterogeneous palladium-based catalysts | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2776389-B1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20150314272-A1 | Conversion Of Alcohols To Alkyl Esters And Carboxylic Acids Using Heterogeneous Palladium-Based Catalysts | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2015-11-05 | — | — | US | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
| US-5939268-A | DIELS-ALDER REACTION PRODUCT OF A DIENE AND A DIENOPHILE; CHEMICAL INTERMEDIATES FOR DRUGS, SOLID PHASE SYNTHESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0773953-A1 | COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME | THE SCRIPPS INSTITUTE (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1996003424-A1 | COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| US-4153795-A | Cobalt pyridyl catalysts for hydroformylation | DIRECTOR-GENERAL OF THE AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150314272-A1 | Conversion Of Alcohols To Alkyl Esters And Carboxylic Acids Using Heterogeneous Palladium-Based Catalysts | ADH5, ADH1A, ADH1C | SMN1; SMN2 3152/4885ALDH1A1 391/4885HRH3 84/4885 |
| US-20170137362-A1 | CONVERSION OF ALCOHOLS TO CARBOXYLIC ACIDS USING HETEROGENEOUS PALLADIUM-BASED CATALYSTS | ADH5, ADH1A, ADH1C | SMN1; SMN2 3295/4885ALDH1A1 296/4885HRH3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.